Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 5, 2011, Pages 289-298

  Aubier, Michel ^a   Haughney, John ^b   Selroos, Olof ^c   Van Schayck, Onno C P ^d   Ekström, Tommy ^e   Ostinelli, Juliette ^f   Buhl, Roland ^g  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Semeco AB   (Sweden)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e ASTRAZENECA R AND D   (Sweden)

^f ASTRAZENECA   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

ACQ5; asthma; baseline steroid dose; budesonide formoterol maintenance and reliever therapy; exacerbations; Symbicort SMART

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID;

ADULT; AGED; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052643636     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811407236     Document Type: Article

References (13)

1. American Thoracic Society (1987) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136: 225–244.
2. Aubier M. Buhl R. Ekstrom T. Ostinelli J. van Schayck C.P. Selroos O. (2010) Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy. Eur Respir J 36: 524–530.
3. Bateman E.D. Reddel H.K. Eriksson G. Peterson S. Östlund O. Sears M.R. (2010) Overall asthma control: The relationship between current control and future risk. J Allergy Clin Immunol 125: 600–608.e6.
4. Buhl R. Vogelmeier C. (2007) Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin 23: 1867–1878.
5. Busse W.W. Chervinsky P. Condemi J. Lumry W.R. Petty T.L. Rennard S. (1998) Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 101: 457–463.
6. Juniper E.F. O'Byrne P.M. Guyatt G.H. Ferrie P.J. King D.R. (1999) Development and validation of a questionnaire to measure asthma control. Eur Respir J 14: 902–907.
7. Juniper E.F. Svensson K. Mörk A.C. Stahl E. (2005) Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 99: 553–558.
8. Miyamoto T. Takahashi T. Nakajima S. Makino S. Yamakido M. Mano K. (2000) A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Japanese Pulmicort Turbuhaler study group. Respirology 5: 247–256.
9. Powell H. Gibson P.G. (2003) Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 178: 223–225.
10. Rabe K.F. Atienza T. Magyar P. Larsson P. Jorup C. Lalloo U.G. (2006) Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368: 744–753.
11. Sears M.R. Radner F. (2009) Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 103: 1960–1968.
12. Selroos O. Backman R. Forsen K.O. Lofroos A.B. Niemisto M. Pietinalho A. (1994) Clinical efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI with volumatic spacer. A 2-year randomized study in 102 asthma patients. Allergy 49: 833–836.
13. Szefler S.J. Martin R.J. King T.S. Boushey H.A. Cherniack R.M. Chinchilli V.M. (2002) Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109: 410–418.